"Die Praxis ist spezialisiert auf die Erkennung und vor allem die Therapie bösartiger Erkrankungen nach modernsten Gesichtspunkten. Dabei spielen neben dem Einsatz von Zytostatika mehr und mehr auch Antikörpertherapien und sogenannte „zielgerichtete&qout; Therapien eine bedeutende Rolle. Dank eines eigenen Studienzentrums sind wir in vielen Fällen in der Lage, Ihnen neben den etablierten Behandlungsmethoden auch neueste Therapieentwicklungen anbieten zu können."

During the past decade, Schwerpunktpraxis für Onkologie/Hämatologie conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Schwerpunktpraxis für Onkologie/Hämatologie" #1 collaborator was "ARCAGY/ GINECO GROUP" with 1 trials as a collaborator, "Arbeitsgemeinschaft Gynaekologische Onkologie Austria" with 1 trials as a collaborator, "Australia New Zealand Gynaecological Oncology Group" with 1 trials as a collaborator and "Scottish Gynaecological Cancer Study Group" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Schwerpunktpraxis für Onkologie/Hämatologie" are "Multiple Myeloma" (1 trials), "Recurrent Ovarian Carcinoma" (1 trials) and "Recurrent Platinum-sensitive Ovarian Cancer" (1 trials). Many other conditions were trialed in "Schwerpunktpraxis für Onkologie/Hämatologie" in a lesser frequency.

Most popular intervention types in "Schwerpunktpraxis für Onkologie/Hämatologie" are "Drug" (3 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Bevacizumab" (2 trials), "Carboplatin" (2 trials), "PLD" (2 trials), "Bortezomib" (1 trials) and "Cisplatin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Schwerpunktpraxis für Onkologie/Hämatologie" are 2 trials for "Female" genders and 1 trials for "All" genders.

Currently, there are NaN active trials in "Schwerpunktpraxis für Onkologie/Hämatologie". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Schwerpunktpraxis für Onkologie/Hämatologie, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Schwerpunktpraxis für Onkologie/Hämatologie, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".